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Condensed Abstract 
A 12-year, bi-institutional, retrospective review showed that Salivary Gland Neoplasm 
of Uncertain Malignant Potential (SUMP) comprised 5.9% (92/1560) of all salivary 
gland aspirates, with an overall risk of malignancy (ROM) of 40.7% (24/59). 
Subtyping SUMP as oncocytic/squamoid, basaloid, or myoepithelial subtypes 
demonstrated differential ROM of 61.1% (11/18), 40.0% (10/25), and 18.8% (3/16), 
respectively (P=0.0476). 
  




The newly unveiled Milan System for Reporting Salivary Gland Cytopathology 
(MSRSGC) has proposed Salivary Gland Neoplasm of Uncertain Malignant Potential 
(SUMP) as an indeterminate category. The category is reserved for fine needle 
aspiration (FNA) cases that are diagnostic of a salivary gland neoplasm but cannot be 
further designated to a specific tumor type. This study aimed to evaluate the clinical 
utility of subtyping SUMP cases based on different cell type. 
 
Methods 
A retrospective search of cytology databases at two institutions for salivary gland 
FNA from 2006-2017 was conducted. The cytologic diagnosis of each case was 
reclassified according to the MSRSGC. Histologic follow-up was retrieved for 
correlation. Cases reclassified as SUMP that had a follow-up pathologic diagnosis 
were subject to cytology review and subtyping into oncocytic/squamoid, basaloid, or 
myoepithelial subtypes based on cytomorphology. The risk of malignancy (ROM) for 
each subtype was analyzed. 
 
Results 
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There were 92 SUMP cases, which comprised 5.9% of 1560 consecutive salivary 
gland FNA within the 12-year period. Histologic follow-up was available in 59 
patients. After cytology review, there were 18 (30.5%) cases of oncocytic/squamoid 
subtype, 25 (42.4%) of basaloid subtype, and 16 (27.1%) of myoepithelial subtype. 
Pathologic correlation revealed ROM of 61.1% (11/18) for oncocytic/squamoid 
subtype, 40.0% (10/25) for basaloid subtype, and 18.8% (3/16) for myoepithelial 




Subtyping SUMP category based on cell type demonstrated differential ROM for 
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Introduction 
Salivary gland fine needle aspiration (FNA) is among the most challenging fields 
in diagnostic cytopathology. The wide morphologic spectrum of salivary gland 
cytology reflects the complexity of salivary gland pathology. There are various types 
of tumors in the salivary glands. The newly updated 2017 World Health Organization 
classification has listed more than 30 types of benign and malignant salivary gland 
epithelial tumors, in addition to other tumors of hematopoietic or soft tissue origins.1 
The morphologic heterogeneity may occur in a single tumor type due to tumor 
differentiation, metaplasia, tissue change or reaction. For example, it is not 
uncommon to see squamous metaplasia or cystic change in a pleomorphic adenoma, 
causing diagnostic confusions.2-5 Moreover, even a single cell type can present with 
diverse cytomorphology. For instance, myoepithelial cells can be spindle-shaped, 
epithelioid, plasmacytoid, or even clear.6 Besides, non-neoplastic tumor-like salivary 
gland lesions as well as other primary tumors occur in lymph node, soft tissue, or skin 
adjacent to the salivary glands can clinically mimic a salivary gland tumor for FNA 
evaluation.7 Therefore, although a specific cytologic diagnosis is not difficult in many 
common salivary gland tumors, rare tumor types, selective sampling, or misleading 
anatomic locations of FNA can sometimes lead to major misdiagnosis.8-10 
The recently unveiled Milan System for Reporting Salivary Gland 
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Cytopathology (MSRSGC) aims to provide an internationally recognized, uniform 
reporting system with standardized terminology to replace the conventional, 
descriptive interpretation for salivary gland FNA.11 The 7-tiered classification 
includes non-diagnostic (I), non-neoplastic (II), atypia of undetermined significance 
(AUS, III), benign neoplasm (IVa), salivary gland neoplasm of uncertain malignant 
potential (SUMP, IVb), suspicious for malignancy (SM, V), and malignant (VI).12 The 
SUMP category is reserved for a small but heterogeneous group of cases with 
cytomorphologic features diagnostic of a neoplasm but indefinitive for a specific 
tumor type to further distinguish between benign or malignant. In our experience, a 
majority of the most formidable salivary gland FNA cases will now be classified 
under this indeterminate diagnostic category. However, the various histologic 
follow-up in this group may cause uncertainty in clinical management. The objectives 
of this current study were to better characterize SUMP cases by subtyping them based 
on different cell type and to evaluate the clinical utility of this practice. 
 
Materials and Methods 
Case Selection 
The study was approved by the Institutional Review Board (IRB) of Taipei 
Veterans General Hospital (IRB No.: 2018-07-009AC) and Indiana University (IRB 
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No.: 1802116631). A retrospective search for cytopathology archives at Taipei 
Veterans General Hospital and Indiana University for salivary gland FNA cases 
during a 12-year period (from January 1st, 2006 to December 31st, 2017) was 
performed. The procedure of salivary gland FNA was similar between the two 
institutions. Briefly, aspirates were performed by surgeons or radiologists with or 
without ultrasonographic guidance using 23- to 25- gauge needles. Two to four passes 
were obtained from each lesion. The smears were prepared with conventional 
methods. The air-dried slides were stained for Romanowsky-type stains (either Liu or 
Diff-Quik) and the alcohol-fixed slides were stained for Papanicolaou stain. Based on 
the cytology reports and slide review when information from the report was 
insufficient, all the cases were reclassified using the recently proposed MSRSGC 
terminology and criteria.12 Clinical information and final pathologic diagnosis were 
recorded from the medical chart. 
 
Slide Review and Subtyping SUMP Cases 
 For cases reclassified as SUMP, all available cytologic slides were retrieved for 
review and subtyping based on cell morphology. The oncocytic/squamoid subtype is 
characterized by epithelial cells with moderate to abundant amounts of cytoplasm. 
The cytoplasm is either granular as it is in oncocytes or dense as in squamoid cells. 
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The nucleus is centrally located and often with a small but distinct nucleolus. The 
distinction between oncocytic and squamoid cells is sometimes unclear; therefore, this 
subtype includes both conditions. Rare cases with foamy or vacuolated cytoplasm are 
also allowed. The differential diagnosis includes Warthin’s tumor, 
oncocytoma/oncocytosis, mucoepidermoid carcinoma, and rarely acinic cell 
carcinoma or secretory carcinoma (Figure 1 and 2). The basaloid subtype is 
characterized by basaloid tumor cells with scant cytoplasm. This subtype is often 
associated with sharply marginated extracellular matrix of various morphologic 
features. The main differential diagnosis is basal cell neoplasm versus adenoid cystic 
carcinoma (Figure 3). The myoepithelial subtype applies to two circumstances. Firstly, 
it can be used for cases showing classic features of benign pleomorphic adenoma, 
while focal cellular atypia is conspicuous (Figure 4A-B). In this situation, the 
differential diagnosis is benign pleomorphic adenoma with focal atypia versus 
non-invasive or invasive carcinoma ex pleomorphic adenoma. For the second 
situation, the cases are composed of predominantly myoepithelial cells but 
chondromyxoid stroma is usually not evident (Figure 4C-D). The main differential 
diagnosis is cellular pleomorphic adenoma versus myoepithelioma or myoepithelial 
carcinoma. 
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Statistical Analyses 
Data were summarized using descriptive statistics. Mean and range were used for 
continuous variables, whereas count and frequency were used for categorical 
variables. Fisher’s exact tests were performed to compare proportions of categorical 
variables. ANOVA tests were performed to test differences among means of multiple 
groups. Two-sided P values < 0.05 were considered to be statistically significant. 




Reclassification of the Study Cohort 
 A total of 1560 salivary gland aspirates was identified (675 from Taipei Veterans 
General Hospital and 885 from Indiana University) in this 12-year period. The result 
of reclassification based on the MSRSGC diagnostic categories was followed: 
non-diagnostic in 293 (18.8%), non-neoplastic in 337 (21.6%), AUS in 60 (3.8%), 
benign neoplasm in 581 (37.2%), SUMP in 92 (5.9%), suspicious for malignancy in 
19 (1.2%), and malignant in 178 (11.4%). Histology follow-up was available in 694 
(44.5%) cases. The risk of malignancy (ROM) for each category was followed: 17.1% 
(12/70) for non-diagnostic, 10.0% (8/80) for non-neoplastic, 37.5% (15/40) for AUS, 
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2.9% (9/315) for benign neoplasm, 40.7% (24/59) for SUMP, 100% (15/15) for 
suspicious for malignancy, and 98.3% (113/115) for malignant. These were 
comparable to the MSRSGC estimated ROM. A summary of this reclassification is 
shown in Table 1. 
 
Clinical Characteristics of SUMP and Subtypes 
 Among the 59 patients who had FNA diagnosis of SUMP and available 
Histologic follow-up, there were 23 men and 36 women with a mean age of 56.3 
years (range, 17-91 years). Fifty-two nodules were from the parotid glands and 7 were 
from the submandibular glands. The mean nodule size was 2.2 cm (range, 0.7-9.4 cm). 
After slide review (J.-F.H. reviewed the slides from Taipei Veterans General Hospital 
and H.H.W. reviewed the slides from Indiana University), the 59 aspirates of SUMP 
were designated to subtypes based on cell type. There were 18 (30.5%) cases of 
oncocytic/squamoid subtype, 25 (42.4%) of basaloid subtype, and 16 (27.1%) of 
myoepithelial subtype. For the myoepithelial subtype, 12 cases showed cellular 
myoepithelial aspirates and 4 showed focal atypia. Ancillary testing was not applied 
in any of the cases. The clinical characteristics are summarized in Table 2. There were 
no significant differences noted with regard to clinical features among patients of 
different SUMP subtypes, except sex (P=0.0379) of which female was more prevalent 
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in myoepithelial subtype. 
 
Pathologic Correlation and ROM for Different SUMP Subtypes 
The follow-up pathologic diagnoses for each SUMP subtype are listed in Table 3. 
Overall, 96.6% (57/59) of FNA diagnosed as SUMP were neoplastic. For 
oncocytic/squamoid subtype, the most common pathology was mucoepidermoid 
carcinoma (38.9%, 7/18) and Warthin’s tumor (16.7%, 3/18). Of note, the only two 
non-neoplastic lesions, one salivary duct cyst and one chronic sialoadenitis, were both 
classified as this subtype. For basaloid subtype, the most common pathology was 
basal cell adenoma (41.7%, 10/24), followed by pleomorphic adenoma (20.8%, 5/24) 
and adenoid cystic carcinoma (16.7%, 4/24). For myoepithelial subtype, the most 
common pathology was pleomorphic adenoma (64.7%, 11/17). 
The ROM for each SUMP subtype is shown in Table 4. The ROM was the 
highest for oncocytic/squamoid subtype (61.1%, 11/18), followed by basaloid subtype 
(40.0%, 10/25) and myoepithelial subtype (18.8%, 3/16). The differences in ROM 
among all three subtypes were statistically significant (P=0.0476). For the comparison 
of ROM between two subtypes, the ROM of oncocytic/squamoid SUMP was 
substantially higher than the myoepithelial SUMP (P=0.0173), while 
oncocytic/squamoid versus basaloid (P=0.2231) and basaloid versus myoepithelial 
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(P=0.1874) were both statistically insignificant. Even though the ROM of 
myoepithelial subtype was the lowest among all SUMP, it was still significantly 
higher than the benign neoplasm category (18.8% vs. 2.9%, P=0.016) 
 
Discussion 
 FNA cytology is widely utilized for the evaluation of salivary gland nodules. It 
shows high specificity in diagnosis of some common benign epithelial neoplasms, 
such as pleomorphic adenoma and Warthin’s tumor,13 as well as frankly malignant 
high-grade carcinomas.14, 15 However, to distinguish between a benign and a 
bland-looking, low- to intermediate-grade malignant tumor can be challenging due to 
cytomorphologic overlap and diversity.7-10 For that reason, the MSRSGC has 
proposed SUMP as an indeterminate diagnostic category.12 This category is reserved 
for FNA cases that are diagnostic of a neoplasm but the possibility of a malignant 
neoplasm cannot be excluded. Previous literatures suggested various approaches on 
the cytologic evaluation of these indeterminate neoplastic lesions. Some illustrated a 
simple scheme by separating these into two groups as basaloid neoplasm and salivary 
gland neoplasm with predominant oncocytic cell,16 while others developed a more 
sophisticated manner considering cell type (basaloid or oncocytoid), variation of 
nuclear size (pleomorphic or monomorphic), stroma (fibrillary, hyaline, or mixed), 
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background materials (cystic, mucinous, or other), and cytoplasmic features 
(granular/vacuolated).17 The MSRSGC has recommended three subcategories for 
SUMP, namely cellular basaloid neoplasm, cellular oncocytic/oncocytoid neoplasm, 
and cellular neoplasm with clear cell features.18 In this current study, we subtyped 
SUMP cases based on three different cell types to comprise most of the diagnostic 
scenarios for indeterminate salivary gland FNA cases according to our own 
experiences. The rationale was to focus on the differential diagnoses associated with 
the three most common benign salivary gland neoplasms, that is, Warthin’s tumor, 
basal cell adenoma, and pleomorphic adenoma, by separating these cases into 
oncocytic/squamoid, basaloid, and myoepithelial subtypes, respectively. Afterward, 
we examined the histologic follow-up and analyzed the ROM for each subtype to 
evaluate the clinical utility of this practice. 
The oncocytic/squamoid subtype is characterized by neoplastic epithelial cells 
with moderate to abundant amounts of granular or dense cytoplasm. The diagnosis of 
benign oncocytic tumors, such as Warthin’s tumor or oncocytoma/oncocytosis, is 
usually not difficult. In occasional cases; however, the presence of atypical features 
like squamous metaplasia, mucinous metaplasia, or mucoid background materials, 
will raise concern of a low-grade mucoepidermoid carcinoma.19 On the other hand, 
when a mucoepidermoid carcinoma shows oncocytoid change, cystic debris, or 
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prominent lymphocytic infiltrates, it may overlap with the cytomorphologic features 
of a benign Warthin’s tumor.20 The histologic follow-up for oncocytic/squamoid 
subtype in this study revealed seven mucoepidermoid carcinomas (Figure 1A and D), 
three Warthin’s tumors (Figure 2A-B), and one oncocytoma (Figure 2C-D). These 
tumors comprised 61.1% (11/18) of the cases. Although cellular neoplasm with clear 
cell features is proposed by the MSRSGC as a SUMP subcategory, we find that there 
is wide cytomorphologic overlap with oncocytic/squamoid subtype cases. Clear cell 
features are generally an artefactual phenomenon in histology due to formalin-fixation. 
The corresponding cytomorphologic features represent granular, foamy, or vacuolated 
cytoplasm, other than clear. The differential diagnoses are seldom benign but rather 
restricted in some less common malignant tumors, such as acinic cell carcinoma,21 
secretory carcinoma,22, 23 hyalinizing clear cell carcinoma,24 clear cell myoepithelial 
carcinoma,25 rare cellular changes of mucoepidermoid carcinoma,26 or metastasis.27 If 
a specific diagnosis cannot be ascertained, this group of tumors may be better 
classified as suspicious for malignancy. In the oncocytic/squamoid subtype of SUMP, 
we accepted rare cases showing abundant foamy or vacuolated cytoplasm as a 
spectrum of oncocytoid cells. There were one acinic cell carcinoma (Figure 1B and E) 
and one secretory carcinoma (Figure 1C and F) on histologic follow-up. Other 
pathology included a salivary duct carcinoma showing scant atypical cells with 
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apocrine features that mimicked oncocytes, a pilomatrixoma presenting as a parotid 
mass and showing scant atypical squamoid cells, a non-neoplastic cyst containing 
abundant mucoid background and scant epithelial cells simulating a mucoepidermoid 
carcinoma, and two lymphoepithelial lesions (one chronic sialoadenitis and one 
extranodal marginal zone B cell lymphoma) resembling Warthin’s tumor. Overall, the 
ROM of oncocytic/squamoid subtype was the highest in this study (61.1%), 
suggesting that surgical management should be highly recommended.  
 The basaloid subtype represents cases showing epithelial tumor cells with scant 
cytoplasm. The cells are often associated with sharply marginated, hyaline-type, 
extracellular matrix, which is better demonstrated by Romanowsky-type stain. To 
differentiate benign versus malignant tumors with basaloid features is a diagnostic 
challenge and sometimes impossible due to overlapping cytomorphology.16, 28-30 In 
addition, certain types of extracellular matrix is non-specific for the diagnosis and 
sometimes misleading. Hyaline globules surrounded by basaloid cells are a 
characteristic feature of adenoid cystic carcinoma. However, this feature has been 
noted in benign basal cell adenoma (Figure 3C-D), pleomorphic adenoma, and 
myoepithelioma, and that may lead to false positive diagnosis.2, 3, 28-30 Hyaline 
globules have also been seen in other malignant tumors like epithelial-myoepithelial 
carcinoma and polymorphous adenocarcinoma of minor salivary glands.31, 32 
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Membranous-type hyaline matrix wrapping around basaloid cell clusters is a common 
feature for basal cell adenoma.30 Although less described in the literature, this feature 
may also present in an adenoid cystic carcinoma with predominant tubular pattern 
(Figure 3A-B), causing false negative diagnosis. Therefore, SUMP category is 
recommended for basaloid neoplasms without unequivocal cytologic features of 
carcinoma to avoid diagnostic discrepancy. Definite diagnosis should not be based on 
types of extracellular matrix alone for these tumors. In this study, the histologic 
follow-up for basaloid subtype showed ten basal cell adenomas, six pleomorphic 
adenomas (including one carcinoma ex pleomorphic adenomas), four adenoid cystic 
carcinomas, and two epithelial-myoepithelial carcinomas. These tumors comprised 
88% (22/25) of the cases. The overall ROM of the basaloid subtype was 40% falling 
between the other two subtypes. 
The myoepithelial subtype is reserved for tumors of myoepithelial differentiation 
showing indeterminate atypical features. The first scenario for this subtype is when 
focal questionable atypia is present in cases showing otherwise characteristic features 
of pleomorphic adenoma. Pleomorphic adenoma is the most common benign salivary 
gland neoplasm. Nevertheless, carcinomas may occasionally arise from pleomorphic 
adenomas and behave aggressively. Selective FNA sampling of carcinoma ex 
pleomorphic adenoma may cause false negative diagnosis. In previous studies, only 
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29-50% of cases had pre-operative FNA diagnosis of malignancy. 33-36 On the other 
hand, various degree of cellular atypia is not uncommon in benign pleomorphic 
adenoma and may be overcalled as malignant.2, 3, 8 In the current study, there was one 
carcinoma ex pleomorphic adenoma out of the four myoepithelial subtype cases of 
focal atypia on histologic follow-up. The other three were all benign pleomorphic 
adenoma (Figure 4A-B). The second scenario applies to cases composed of 
predominately myoepithelial cells. The myoepithelial cells are often plasmacytoid 
with diffuse mild to moderate atypia (Figure 4C-D). The extracellular stroma may be 
present but usually not chondromyxoid in texture. The main differential diagnosis 
included cellular pleomorphic adenoma, myoepithelioma, basal cell neoplasm, and 
myoepithelial carcinoma.6, 29 In this study, the histologic follow-up for cellular 
myoepithelial aspirates revealed 11 pleomorphic adenomas, one basal cell adenoma, 
one myoepithelial carcinoma, and one adenoid cystic carcinoma. Overall, the ROM 
for the myoepithelial subtype of SUMP was the lowest; however, it was still 
significantly higher than the benign neoplasm category (18.8% vs. 2.9%, P=0.016). 
The recent molecular advances reveal several type-specific genetic alterations in 
salivary gland tumors.37 Ancillary testing such as immunocytochemistry, fluorescent 
in-situ hybridization, or polymerase chain reaction has emerged and been increasingly 
used in cytopathology.32, 38, 39 Nonetheless, more studies are still required to validate 
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the performance of these tests on cytologic specimens. Given that complete surgical 
excision is the standard treatment for most symptomatic salivary gland tumors, FNA 
confirmation of a neoplastic lesion is sufficient for following clinical management. A 
type-specific diagnosis seldom changes the procedure. For a practical point of view, 
imaging evaluation of the tumor border may provide further information regarding the 
extent of surgery.40 
In conclusions, SUMP is a robust diagnostic category that comprised 5.9% of the 
total salivary gland FNA cases in this 12-year retrospective review. Among them, 
96.6% had confirmed neoplastic diagnoses upon follow-up. Subtyping SUMP cases 
demonstrated differential ROM for oncocytic/squamoid (61.1%), basaloid (40.0%), 
and myoepithelial subtypes (18.8%) (P=0.0476). This simple and practical approach 
facilitates clinical stratification. Future prospective studies are mandatory to confirm 
this finding. 
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Figure Legends 
Figure 1. Oncocytic/squamoid subtype with malignant follow-up. (A) Oncocytoid 
cells with moderate amounts of cytoplasm admixed with few lymphocytes (Liu stain, 
X400). Follow-up excision showed an intermediate-grade mucoepidermoid carcinoma 
with prominent lymphocytic cuffing (D, H&E, X100). (B) Cellular fragments 
consisted of oncocytoid cells with finely granular cytoplasm (Papanicolaou, X400). 
Follow-up excision showed an acinic cell carcinoma (E, H&E, X200). (C) Loosely 
cohesive cell fragments comprised oncocytoid cells with dense cytoplasm. 
Proteinaceous fluid was noted in the background (Liu stain, X200). Follow-up 
excision showed a secretory carcinoma (F, H&E, X200).  
 
Figure 2. Oncocytic/squamoid subtype with benign follow-up. (A) Squamoid cell 
clusters noted in a background of mucoid material and granular debris (Papanicolaou, 
X200). (B) Follow-up excision showed a Warthin’s tumor with focal mucinous and 
squamous metaplasia (H&E, X200). (C) Large, thickened cell fragments consisted of 
monotonous oncocytic/squamoid cells. The background was relatively clean 
(Papanicolaou, X200). (D) Follow-up excision showed an oncocytoma (H&E, X200). 
 
Figure 3. Basaloid subtype. (A) Basaloid cell fragments showed membranous 
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extracellular matrix. The cells were devoid of atypia (Liu stain, X400). (B) Follow-up 
excision showed an adenoid cystic carcinoma with predominant tubular growth 
pattern (H&E, X200). (C) A cribriform cell cluster featured magenta-colored hyaline 
globules (Liu stain, X400). (D) Follow-up excision showed a basal cell adenoma with 
multiple microcysts containing basophilic substance. The tumor was well 
circumscribed with a thick fibrous capsule (H&E, X40). 
 
Figure 4. Myoepithelial subtype. (A) Focal atypical cells with anisonucleosis and 
prominent nucleoli in a background of scant fibrillary stroma were noted, while the 
rest of the smear demonstrated classic features of a benign pleomorphic adenoma (Liu 
stain, X400). (B) The following parotidectomy specimen was totally embedded for 
sections and showed a benign pleomorphic adenoma with focal atypia (H&E, X200). 
(C) A cellular smear showed discohesive, plasmacytoid myoepithelial cells. Diffuse, 
mild to moderate atypia with anisonucleosis, binucleation, and distinct nucleoli were 
noted. There was no extracellular matrix identified on the smear (Liu stain, X400). (D) 
Follow-up excision showed a cellular pleomorphic adenoma (H&E, X200). 
 
